EUVIMEDEUVIMED entdecken
LeserbriefKommentar

HER2-Low Breast Cancer Can Be Visualized by HER2 PET

Renske Altena, Siri Af Burén, Thuy Tran, Rimma Axelsson

Journal of Nuclear Medicine · 2023

DOI: 10.2967/jnumed.123.266101 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Renske Altena und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TO THE EDITOR: We would like to comment on the letter from Seban et al. to the editor of The Journal of Nuclear Medicine in the July issue ([1][1]). The results from the DESTINY-Breast04 trial, receiving a standing ovation during the presidential symposium at the annual conference of the American

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemalePositron Emission Tomography Computed TomographyPositron-Emission TomographyErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18

Substanzen

Erb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18

Zitieren

APA

Altena, R., Af Burén, S., Tran, T., & Axelsson, R. (2023). HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266101

Vancouver

Altena R, Af Burén S, Tran T, Axelsson R. HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.266101

BibTeX
@article{Altena2023,
  author = {Altena, Renske and Af Burén, Siri and Tran, Thuy and Axelsson, Rimma},
  title = {HER2-Low Breast Cancer Can Be Visualized by HER2 PET},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  doi = {10.2967/jnumed.123.266101}
}
Kostenlos starten →